Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Proof of Principle Program - Phase I

University of Toronto

$160,000.00

Highly specific therapeutic-grade anti-FGFR1 antibodies with anti-proliferative effects

EF 2014-15

Résumé
Cancer arises when cells multiply in an uncontrolled manner. In normal cells, growth is controlled by signals that regulate the production of proteins involved in cell division. Receptors located on the surface of cells transmit these signals to the inside of cells where protein production occurs. Abnormal receptor function can lead to loss of control of cell multiplication, and tumors. Many such receptors are known to have deregulated function in cancer. Therefore, one therapeutic route is to block the ability of the receptors to propagate the signals into cells. Antibodies, which can attach to receptors and block their function, are one class of biological drugs that have been developed for this purpose. We have focused on developing antibodies against the Fibroblast Growth Factor Receptor (FGFR) family of receptors, which are involved in several cancers, including lung, bone and breast cancers. In particular, FGFR1 activity is an important driver of increased cell division, so we aimed to produce antibodies that affect only this receptor, and not other FGFRs. We generated blocking synthetic antibodies to FGFR1, which showed efficacy at reducing tumor growth, but led to an undesirable side effect (weight loss). We also generated antibodies to FGFR2, and subsequently showed that some of these antibodies were able to block FGFR1 as well, and were effective at reducing tumor growth without affecting weight. Therefore, the goal of this study is to improve FGFR1 antibodies by 1) achieving specificity to FGFR1 with no activity on other FGFRs and 2) increasing how tightly the antibody binds to FGFR1 to obtain therapeutic-grade antibodies. Ultimately, we seek to produce an antibody effective at reducing multiplication of human cancer cells, and leading to reduced tumor growth and increased survival in animal models, without causing undesired side effects. This antibody drug will be ready for clinical testing as a potential novel therapy for cancer.
Programme
Proof of Principle Program - Phase I
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
325129
Name
Sidhu Sachdev S
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Proof of Principle
Projecttitle
Highly specific therapeutic-grade anti-FGFR1 antibodies with anti-proliferative effects
Programtype2
Operating Grants
Orgnameinp2
University of Toronto
Cihramount2
$160,000
Cihrequipment2
$0
Programname2
Proof of Principle Program - Phase I
Keyworddelim
Antibodies; Antibody-Mediated Inhibition; Cell Signaling; Cell Surface Receptor; Combinatorial Libraries; Fibroblast Growth Factor Receptor; High Throughput Screening; Phage Display; Protein Engineering; Targeted Cancer Therapy
Abstract
Cancer arises when cells multiply in an uncontrolled manner. In normal cells, growth is controlled by signals that regulate the production of proteins involved in cell division. Receptors located on the surface of cells transmit these signals to the inside of cells where protein production occurs. Abnormal receptor function can lead to loss of control of cell multiplication, and tumors. Many such receptors are known to have deregulated function in cancer. Therefore, one therapeutic route is to block the ability of the receptors to propagate the signals into cells. Antibodies, which can attach to receptors and block their function, are one class of biological drugs that have been developed for this purpose. We have focused on developing antibodies against the Fibroblast Growth Factor Receptor (FGFR) family of receptors, which are involved in several cancers, including lung, bone and breast cancers. In particular, FGFR1 activity is an important driver of increased cell division, so we aimed to produce antibodies that affect only this receptor, and not other FGFRs. We generated blocking synthetic antibodies to FGFR1, which showed efficacy at reducing tumor growth, but led to an undesirable side effect (weight loss). We also generated antibodies to FGFR2, and subsequently showed that some of these antibodies were able to block FGFR1 as well, and were effective at reducing tumor growth without affecting weight. Therefore, the goal of this study is to improve FGFR1 antibodies by 1) achieving specificity to FGFR1 with no activity on other FGFRs and 2) increasing how tightly the antibody binds to FGFR1 to obtain therapeutic-grade antibodies. Ultimately, we seek to produce an antibody effective at reducing multiplication of human cancer cells, and leading to reduced tumor growth and increased survival in animal models, without causing undesired side effects. This antibody drug will be ready for clinical testing as a potential novel therapy for cancer.
Competitiondate
201502
Approvedterm2
1 yr 0 mth
Pinamesdelim
Sidhu, Sachdev S
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $160,000~ $0~